Deep intrmuscular methylprednisolone treatment of recurrent scleritis

S Deokule, T Saeed, Philip Murray

Research output: Contribution to journalArticle

1 Citation (Scopus)


Purpose: To evaluate the efficacy of deep intramuscular methyl-prednisolone (IMMP) in the treatment of recurrent scleritis. Methods: A total of 15 patients with scleritis (12 anterior, 3 pan) underwent IMMP injection deep into the thigh. Thirteen patients were already being treated with oral non-steroidal anti-inflammatory drugs, oral prednisolone, an oral immunosuppressive agent, or a combination of these drugs. A second IMMP injection was given to nine patients, making a total of 24 injections. Follow-up ranged from 4 to 18 months. Results: There was a documented improvement in scleritis after 21/24 (87.3%) injections with a mean duration of improvement of 5.7 months. No patient required the introduction of oral corticosteroid or immunosuppressive agent, and only one patient required an increase in methotrexate to control the disease. No systemic, injection site, or ocular side effects were noted. Conclusions: Deep IMMP is a safe and effective treatment for scleritis. It ensures compliance, avoids the systemic side effects of oral corticosteroids, and is easily repeatable in the outpatient setting.
Original languageEnglish
Pages (from-to)67-71
Number of pages5
JournalOcular immunology and inflammation
Publication statusPublished - 1 Jan 2005


  • treatment
  • methylprednisolone
  • scleritis
  • outcome
  • intramuscular


Dive into the research topics of 'Deep intrmuscular methylprednisolone treatment of recurrent scleritis'. Together they form a unique fingerprint.

Cite this